
Merck’s Covid-19 pill cuts risk of death, hospitalization by 50%
Merck & Co Inc’s experimental oral drug for COVID-19, molnupiravir, reduced by around 50% the chance of hospitalization or death for patients at risk of severe disease, according to interim ...